Thus anti-PD-1/PD-L1 antibodies could be an optional therapy for advanced NSCLC patients, especially for EGFR-TKIs resistant NSCLC patients with EGFR mutation [9, 13–15]. Here, PDCD1 is linked to non-small cell lung carcinoma.